Dermata Therapeutics (DRMA) Competitors $0.70 0.00 (-0.61%) As of 07/25/2025 03:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRMA vs. GELS, VYNE, DRRX, CYCC, LPCN, MRKR, HOTH, PASG, EDSA, and PRPHShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Gelteq (GELS), VYNE Therapeutics (VYNE), DURECT (DRRX), Cyclacel Pharmaceuticals (CYCC), Lipocine (LPCN), Marker Therapeutics (MRKR), Hoth Therapeutics (HOTH), Passage Bio (PASG), Edesa Biotech (EDSA), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. Its Competitors Gelteq VYNE Therapeutics DURECT Cyclacel Pharmaceuticals Lipocine Marker Therapeutics Hoth Therapeutics Passage Bio Edesa Biotech ProPhase Labs Dermata Therapeutics (NASDAQ:DRMA) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends. Does the media refer more to DRMA or GELS? In the previous week, Dermata Therapeutics and Dermata Therapeutics both had 1 articles in the media. Dermata Therapeutics' average media sentiment score of 1.89 beat Gelteq's score of 0.94 indicating that Dermata Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Dermata Therapeutics Very Positive Gelteq Positive Do insiders and institutionals hold more shares of DRMA or GELS? 8.7% of Dermata Therapeutics shares are held by institutional investors. 18.5% of Dermata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer DRMA or GELS? Dermata Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 329.06%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Dermata Therapeutics is more favorable than Gelteq.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Gelteq 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings & valuation, DRMA or GELS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDermata TherapeuticsN/AN/A-$12.29M-$16.41-0.04GelteqN/AN/A-$2.33MN/AN/A Is DRMA or GELS more profitable? Gelteq's return on equity of 0.00% beat Dermata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dermata TherapeuticsN/A -270.81% -179.96% Gelteq N/A N/A N/A SummaryDermata Therapeutics beats Gelteq on 6 of the 9 factors compared between the two stocks. Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMA vs. The Competition Export to ExcelMetricDermata TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.46M$3.06B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-0.0421.1828.1020.05Price / SalesN/A288.50432.4490.07Price / CashN/A42.7636.2258.56Price / Book1.138.378.665.87Net Income-$12.29M-$55.19M$3.25B$258.55M7 Day Performance3.28%5.88%4.23%3.74%1 Month Performance19.32%17.33%10.52%11.75%1 Year Performance-69.20%4.42%34.41%18.03% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMADermata Therapeutics2.7921 of 5 stars$0.700.0%$3.00+329.1%-72.9%$4.46MN/A-0.048Positive NewsGELSGelteqN/A$1.89+3.3%N/AN/A$17.84M$100K0.00N/AGap UpVYNEVYNE Therapeutics2.9491 of 5 stars$1.17-3.4%$6.25+434.6%-30.5%$17.77M$500K-1.1830DRRXDURECT1.1933 of 5 stars$0.57+0.9%N/A-65.6%$17.69M$2.03M-3.8080Positive NewsGap DownCYCCCyclacel Pharmaceuticals1.1778 of 5 stars$11.17-4.2%N/A-96.0%$17.54M$40K-0.0114Gap DownLPCNLipocine2.8716 of 5 stars$3.24+2.2%$9.00+177.8%-40.9%$17.33M$11.20M-3.1810MRKRMarker Therapeutics4.5789 of 5 stars$1.53-0.1%$13.17+761.1%-70.2%$17.26M$6.59M-1.1560HOTHHoth Therapeutics2.9209 of 5 stars$1.31-1.1%$4.00+206.5%+58.0%$17.24MN/A-1.144Analyst ForecastGap UpPASGPassage Bio3.3868 of 5 stars$5.49+4.3%$150.00+2,630.3%-57.7%$17.08MN/A-0.27130News CoveragePositive NewsInsider TradeGap UpHigh Trading VolumeEDSAEdesa Biotech2.3532 of 5 stars$2.40-0.6%$5.00+108.8%-53.2%$16.78MN/A-1.5020Positive NewsPRPHProPhase Labs0.3945 of 5 stars$0.39-2.7%N/A-84.6%$16.37M$6.77M-0.31130Gap Up Related Companies and Tools Related Companies GELS Competitors VYNE Competitors DRRX Competitors CYCC Competitors LPCN Competitors MRKR Competitors HOTH Competitors PASG Competitors EDSA Competitors PRPH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRMA) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRMA Stock Alerts